GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » EV-to-EBIT

StemRIM (TSE:4599) EV-to-EBIT : -7.37 (As of Jun. 18, 2024)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, StemRIM's Enterprise Value is 円15,686 Mil. StemRIM's EBIT for the trailing twelve months (TTM) ended in Apr. 2024 was 円-2,129 Mil. Therefore, StemRIM's EV-to-EBIT for today is -7.37.

The historical rank and industry rank for StemRIM's EV-to-EBIT or its related term are showing as below:

TSE:4599' s EV-to-EBIT Range Over the Past 10 Years
Min: -80.22   Med: -22.44   Max: 360.27
Current: -7.36

During the past 7 years, the highest EV-to-EBIT of StemRIM was 360.27. The lowest was -80.22. And the median was -22.44.

TSE:4599's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 9.37 vs TSE:4599: -7.36

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. StemRIM's Enterprise Value for the quarter that ended in Apr. 2024 was 円19,924 Mil. StemRIM's EBIT for the trailing twelve months (TTM) ended in Apr. 2024 was 円-2,129 Mil. StemRIM's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2024 was -10.69%.


StemRIM EV-to-EBIT Historical Data

The historical data trend for StemRIM's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM EV-to-EBIT Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
EV-to-EBIT
Get a 7-Day Free Trial - 99.36 -50.11 -21.08 271.08

StemRIM Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.05 271.08 137.65 135.50 -9.36

Competitive Comparison of StemRIM's EV-to-EBIT

For the Biotechnology subindustry, StemRIM's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where StemRIM's EV-to-EBIT falls into.



StemRIM EV-to-EBIT Calculation

StemRIM's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15685.795/-2129.233
=-7.37

StemRIM's current Enterprise Value is 円15,686 Mil.
StemRIM's EBIT for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,129 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM  (TSE:4599) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

StemRIM's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Apr. 2024 ) =EBIT / Enterprise Value (Q: Apr. 2024 )
=-2129.233/19923.9076
=-10.69 %

StemRIM's Enterprise Value for the quarter that ended in Apr. 2024 was 円19,924 Mil.
StemRIM's EBIT for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,129 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of StemRIM's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM (TSE:4599) Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM (TSE:4599) Headlines

No Headlines